• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characteristics of expedited programmes for cancer drug approval in China.

作者信息

Li Guanqiao, Liu Yang, Xie Cuicui, Zhou Qing, Chen Xiaoyuan

出版信息

Nat Rev Drug Discov. 2021 Jun;20(6):416. doi: 10.1038/d41573-021-00080-0.

DOI:10.1038/d41573-021-00080-0
PMID:33972774
Abstract
摘要

相似文献

1
Characteristics of expedited programmes for cancer drug approval in China.中国癌症药物加速审批程序的特点。
Nat Rev Drug Discov. 2021 Jun;20(6):416. doi: 10.1038/d41573-021-00080-0.
2
Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.美国食品和药物管理局批准用于治疗主要癌症与次要癌症的药物的监管特点和关键研究设计。
Eur J Clin Pharmacol. 2019 Sep;75(9):1193-1200. doi: 10.1007/s00228-019-02695-0. Epub 2019 May 25.
3
India spurns cancer patents.印度拒绝癌症专利。
Nature. 2013 Aug 15;500(7462):266. doi: 10.1038/500266a.
4
China tightens up.中国收紧管控。
Nature. 2007 Aug 9;448(7154):636-7. doi: 10.1038/448636a.
5
A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.一项关于 2010 年至 2018 年间 3 个监管机构的抗肿瘤药物试验人群与批准治疗适应证之间差异的定性研究。
Clin Ther. 2020 Feb;42(2):305-320.e0. doi: 10.1016/j.clinthera.2020.01.002. Epub 2020 Jan 31.
6
China syndrome--a regulatory framework in meltdown?中国综合症——监管框架正在崩溃？
Nat Biotechnol. 2007 Aug;25(8):835-7. doi: 10.1038/nbt0807-835. Epub 2007 Aug 2.
7
Report blames NICE for hastening decline of UK biotech.报告指责英国国家卫生与临床优化研究所（NICE）加速了英国生物技术行业的衰落。
Nat Biotechnol. 2009 Mar;27(3):215-7. doi: 10.1038/nbt0309-215.
8
Approvals in 2016: questioning the clinical benefit of anticancer therapies.2016年的批准情况：质疑抗癌疗法的临床益处。
Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.
9
This Time I Mean It!这次我是认真的！
J Natl Compr Canc Netw. 2020 Jan;18(1):1. doi: 10.6004/jnccn.2020.0003.
10
Oncology approvals in 2020: a year of firsts in the midst of a pandemic.2020 年肿瘤学审批：大流行期间的首例之年。
Nat Rev Clin Oncol. 2021 Mar;18(3):129-130. doi: 10.1038/s41571-021-00477-1.

引用本文的文献

1
Promoting the development and approval of new traditional Chinese medicines in China: a pooled analysis of data from 2013 to 2024.推动中国新型中药的研发与审批：2013年至2024年数据的汇总分析
Front Med (Lausanne). 2025 Jun 16;12:1559703. doi: 10.3389/fmed.2025.1559703. eCollection 2025.
2
Characteristics, clinical evidence and implementation effects of conditional approvals for drugs in China, a pooled analysis from 2020 to 2023.中国药品附条件批准的特征、临床证据及实施效果：2020至2023年汇总分析
Front Pharmacol. 2025 Apr 25;16:1501525. doi: 10.3389/fphar.2025.1501525. eCollection 2025.
3
Comparative Assessment of Pivotal Trials Supporting the Indication Approvals of Innovative and Modified New Anticancer Drugs in China, 2016-2022.
2016 - 2022年中国创新型和改良型新型抗癌药物适应症批准的关键试验对比评估
Health Data Sci. 2025 May 2;5:0263. doi: 10.34133/hds.0263. eCollection 2025.
4
Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis.中国政府医保谈判后PD-1药物价格、销量及支出变化评估：多治疗期中断时间序列分析
J Glob Health. 2025 Apr 18;15:04069. doi: 10.7189/jogh.15.04069.
5
Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024.2020-2024 年中国突破性治疗药物认定的癌症药物的临床获益、价格和监管批准。
JAMA Netw Open. 2024 Oct 1;7(10):e2439080. doi: 10.1001/jamanetworkopen.2024.39080.
6
Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval.2020年中美两国抗癌新药进展：从临床试验到药物获批
J Natl Cancer Cent. 2021 Aug 22;1(4):147-152. doi: 10.1016/j.jncc.2021.08.002. eCollection 2021 Dec.
7
Growing research and development of targeted anticancer drugs in China.中国靶向抗癌药物的研发日益增多。
J Natl Cancer Cent. 2023 Apr 19;3(2):129-134. doi: 10.1016/j.jncc.2023.02.004. eCollection 2023 Jun.
8
Efficacy and Safety of Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People's Republic of China: a Systematic Review and Meta-Analysis.抗程序性细胞死亡蛋白1/程序性死亡配体1抗体联合化疗作为中国非小细胞肺癌一线治疗的疗效与安全性：一项系统评价与Meta分析
JTO Clin Res Rep. 2024 Apr 29;5(6):100678. doi: 10.1016/j.jtocrr.2024.100678. eCollection 2024 Jun.
9
Innovation drug approvals based on a bridging study: from concept to practice.基于桥接研究的创新药物批准：从概念到实践。
Transl Breast Cancer Res. 2022 Jan 31;3:2. doi: 10.21037/tbcr-21-43. eCollection 2022.
10
Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.2001 - 2020年中国和美国癌症药物适应症批准情况：批准时间与临床获益比较
Lancet Reg Health West Pac. 2024 Apr 2;45:101055. doi: 10.1016/j.lanwpc.2024.101055. eCollection 2024 Apr.